New Impact Factor for Chinese Clinical Oncology: 2.1

Published: 2024-06-21

We are pleased to announce that the Chinese Clinical Oncology (CCO) has attained its latest impact factor for the 2023 citation year: 2.1 (Figure 1).

Figure 1. Journal Impact Factor of CCO.

Chinese Clinical Oncology (CCO; Chin Clin Oncol; Print ISSN 2304 - 3865; Online ISSN 2304 - 3873) is an Open Access, peer-reviewed, bimonthly journal (quarterly published from Sep 2012 - Dec 2015). CCO has been indexed in MEDLINE / PubMed since 2014 and Emerging Sources Citation Index (ESCI) since 2016. The main focus of the journal is to describe new findings in the field of oncology and to provide current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention and technical advances related to cancer.

We strive to follow the best practices in publishing. The announcement of the journal’s latest impact factor is not only a significant achievement for the journal but also the recognition of its more significant scientific reach. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors, and reviewers for their significant contributions.

We look forward to the continuous cooperation with all the individuals mentioned above and those who are interested in cancer research to bring more exciting content to readers in the coming future.

Editorial Office
Chinese Clinical Oncology

June 20, 2024